• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Septax
    / BioAvenir


    Active Ingredient
    Ceftazidime (as Pentahydrate) 1 g, 2 g

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 X 1 g

    partial basket chart 6442 19962

    Vial

    1 X 2 g

    partial basket chart 6443 19963

    Dosage

    Ceftazidime is to be used by the parenteral route, the dosage depending upon
    the severity, sensitivity and type of infection and the age, weight and renal
    function of the patient.
    Adults: The adult dosage range for ceftazidime is 1 to 6 g per day 8 or 12 hourly
    (i.m. or i.v.). In the majority of infections, l g 8-hourly or 2 g 12-hourly should be given. In urinary tract infections and in many less serious infections, 500 mg or 1 g 12-hourly is usually adequate. In very severe infections, especially immunocompromised patients, including those with neutropenia, 2 g 8 or 12-hourly or 3 g 12-hourly should be administered.
    When used as a prophylactic agent in prostatic surgery 1 g (from the 1 g vial) should be given at the induction of anaesthesia. A second dose should be considered at the time of catheter removal.
    Elderly: In view of the reduced clearance of ceftazidime in acutely ill elderly
    patients, the daily dose should not normally exceed 3 g, especially in those
    over 80 years of age.
    Cystic fibrosis: In fibrocystic adults with normal renal function who have pseudomonal lung infections, high doses of 100 to 150 mg/kg/day as three divided doses should be used. In adults with normal renal function 9 g/day has been used without ill effect.
    Infants and children: The usual dosage range for children aged over two months is 30 to 100 mg/kg/day, given as two or three divided doses.
    Doses up to 150 mg/kg/day (maximum 6 g daily) in three divided doses may
    be given to infected immunocompromised or fibrocystic children or children
    with meningitis.
    Neonates and children up to 2 months of age: Whilst clinical experience in limited, a dose of 25 to 60 mg/kg/day given as two divided doses has proved to be effective. In the neonate the serum halflife of ceftazidime can be three to four times that in adults.
    Dosage in impaired renal function: Ceftazidime is excreted by the kidneys almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function it is recommended that the dosage of ceftazidime should be reduced to compensate for its slower excretion, except in mild impairment, i.e.
    glomerular filtration rate (GFR) greater than 50 ml/min . In patients with suspected renal insufficiency, an initial loading dose of 1 g of ceftazidime may be given. An estimate of GFR should be made to determine the appropriate maintenance dose.
    Renal impairment: For patients in renal failure on continuous arteriovenous haemodialysis or high-flux haemofiltration in intensive therapy units, it is recommended that the dosage should be 1 g daily in divided doses. For low-flux haemofiltration it is recommended that the dosage should be that suggested under impaired renal function.
    See prescribing information for full details.


    Indications

    Treatment of single or multiple infections caused by susceptible microorganisms.


    Contra-Indications

    Ceftazidime is contra-indicated in patients with known hypersensitivity to
    cephalosporin antibiotics.


    Special Precautions

    Use during pregnancy only if clearly needed. Caution should be exercised when administered to nursing mothers. Safety and effectiveness in infants under 6 months of age have not been established.
    See prescribing information for full details.


    Side Effects

    Generally well tolerated.
    See prescribing information for full details.


    Manufacturer
    Vianex
    Licence holder
    CLOSE